This study will determine whether treatment with AMG 162 can prevent lumbar spine bone loss in both early and late postmenopausal women with osteopenia, and to further test the safety and tolerability of AMG 162 in this population.

Condition	Treatment or Intervention	Phase
Postmenopausal Osteoporosis	Drug: AMG 162	Phase III

Ages Eligible for Study:  up to  90 Years,  Genders Eligible for Study:  Female

Criteria

Eligibility Criteria:

• Postmenopausal women with Osteopenia (lumbar spine bone mineral density [BMD] T-score between 1.0 and -2.5)

California
      Research Site, Laguna Hills,  California,  United States
      Research Site, Upland,  California,  United States
Florida
      Research Site, Lake Worth,  Florida,  United States
      Research Site, Leesburg,  Florida,  United States
Georgia
      Research Site, Decatur,  Georgia,  United States
Hawaii
      Research Site, Honolulu,  Hawaii,  United States
Maryland
      Research Site, Bethesda,  Maryland,  United States
      Research Site, Laurel,  Maryland,  United States
Michigan
      Research Site, Detroit,  Michigan,  United States
Nebraska
      Research Site, Omaha,  Nebraska,  United States
New Mexico
      Research Site, Albuquerque,  New Mexico,  United States
Oregon
      Research Site, Portland,  Oregon,  United States
Pennsylvania
      Research Site, Duncansville,  Pennsylvania,  United States
Texas
      Research Site, San Antonio,  Texas,  United States
Virginia
      Research Site, Richmond,  Virginia,  United States

Study ID Numbers:  20040132
Record last reviewed:  February 2005
Last Updated:  February 23, 2005
Record first received:  September 17, 2004
ClinicalTrials.gov Identifier:  NCT00091793
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08